Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹79Cr
Rev Gr TTM
Revenue Growth TTM
10.39%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

ARISTO
VS
| Quarter | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | | 39.3 | 21.5 | 2.9 | 26.5 | 61.2 | -7.5 | 19.8 |
| 88 | 72 | 124 | 85 | 128 | 109 | 206 | 103 | 249 |
Operating Profit Operating ProfitCr |
| 4.7 | 1.2 | 3.9 | 4.1 | 4.0 | 2.9 | 3.8 | 1.1 | 3.1 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
Depreciation DepreciationCr | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| 3 | 0 | 4 | 2 | 4 | 3 | 7 | 1 | 7 |
| 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 |
|
Growth YoY PAT Growth YoY% | | | 46.3 | 403.0 | -0.8 | 32.0 | 77.0 | -137.1 | -8.3 |
| 1.9 | -0.5 | 2.0 | 1.1 | 1.9 | 1.2 | 2.1 | -0.5 | 1.6 |
| 0.0 | 0.0 | 0.0 | 1.5 | 3.8 | 1.9 | 6.7 | -0.7 | 6.1 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 180.3 | 69.6 | -25.7 | -0.2 | -16.9 | -0.9 | 31.4 | 12.5 | 29.8 | 13.3 |
| 56 | 158 | 264 | 195 | 197 | 163 | 161 | 209 | 237 | 309 | 351 |
Operating Profit Operating ProfitCr |
| 1.6 | 1.6 | 2.7 | 3.4 | 2.2 | 2.6 | 3.1 | 4.0 | 3.5 | 2.9 | 2.5 |
Other Income Other IncomeCr | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 1 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | 2 | 2 |
Depreciation DepreciationCr | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 |
| 1 | 3 | 6 | 4 | 1 | 2 | 2 | 5 | 5 | 5 | 8 |
| 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | 1 | 1 |
|
| | 365.3 | 101.9 | -24.3 | -64.4 | 6.8 | 33.3 | 148.4 | 9.4 | 4.3 | -9.4 |
| 0.7 | 1.2 | 1.4 | 1.4 | 0.5 | 0.6 | 0.9 | 1.6 | 1.6 | 1.3 | 1.0 |
| 4.0 | 18.5 | 37.4 | 5.7 | 2.0 | 2.1 | 2.9 | 5.2 | 5.7 | 6.0 | 5.4 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Equity Capital Equity CapitalCr | 1 | 1 | 1 | 5 | 5 | 5 | 5 | 7 | 7 | 7 |
| 2 | 4 | 7 | 6 | 7 | 8 | 10 | 23 | 27 | 31 |
Current Liabilities Current LiabilitiesCr | 24 | 78 | 70 | 72 | 65 | 56 | 51 | 59 | 84 | 96 |
Non Current Liabilities Non Current LiabilitiesCr | 0 | 5 | 11 | 7 | 11 | 12 | 11 | 10 | 10 | 8 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 25 | 84 | 81 | 81 | 77 | 69 | 63 | 83 | 105 | 116 |
Non Current Assets Non Current AssetsCr | 2 | 3 | 8 | 10 | 11 | 12 | 14 | 17 | 22 | 25 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 1 | -4 | 1 | 8 | 1 | 2 | 7 | -3 | 8 | 10 |
Investing Cash Flow Investing Cash FlowCr | 0 | 0 | -5 | -2 | -2 | -2 | -3 | -4 | -7 | -5 |
Financing Cash Flow Financing Cash FlowCr | 0 | 4 | 4 | -6 | 1 | -1 | -3 | 8 | -2 | -4 |
|
Free Cash Flow Free Cash FlowCr | 0 | -4 | 0 | 8 | 1 | 1 | 4 | -5 | 1 | 5 |
| 155.4 | -214.6 | 22.8 | 288.1 | 139.7 | 212.3 | 472.7 | -78.1 | 195.1 | 246.5 |
CFO To EBITDA CFO To EBITDA% | 65.9 | -157.5 | 11.6 | 119.5 | 31.2 | 52.6 | 131.0 | -32.0 | 89.5 | 108.0 |
| Financial Year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 43 | 79 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.7 | 10.9 | 19.5 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.3 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.3 | 2.1 |
| 4.5 | 3.9 | 2.7 | 2.0 | 4.3 | 5.1 | 4.8 | 6.8 | 7.4 | 10.8 |
Profitability Ratios Profitability Ratios |
| 11.5 | 7.9 | 7.7 | 8.7 | 6.8 | 10.3 | 11.3 | 10.1 | 7.7 | 7.1 |
| 1.6 | 1.6 | 2.7 | 3.4 | 2.2 | 2.6 | 3.1 | 4.0 | 3.5 | 2.9 |
| 0.7 | 1.2 | 1.4 | 1.4 | 0.5 | 0.6 | 0.9 | 1.6 | 1.6 | 1.3 |
| 14.2 | 23.6 | 26.1 | 24.7 | 12.5 | 10.1 | 10.8 | 14.2 | 13.0 | 12.0 |
| 13.8 | 39.1 | 44.1 | 25.0 | 8.2 | 8.0 | 9.7 | 11.8 | 11.6 | 10.9 |
| 1.5 | 2.1 | 4.2 | 3.1 | 1.1 | 1.3 | 1.9 | 3.6 | 3.1 | 2.9 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
Aristo Bio-Tech and Life Science Limited (NSE: **ARISTO**) is a prominent Indian agrochemical player specializing in the manufacturing, formulation, supply, and packaging of crop protection solutions. The company serves as a critical link in the agricultural value chain, providing a diverse range of products designed to mitigate crop loss—which currently claims **30-35%** of India’s annual yield—and enhance global food security.
---
### **Integrated Business Model & Service Architecture**
Aristo operates a dual-revenue model that combines proprietary product sales with high-value contract manufacturing and professional consultancy.
* **Agrochemical Manufacturing & Formulation:** The company produces a comprehensive portfolio including **Insecticides, Herbicides, Fungicides, and Plant Growth Regulators**.
* **Contract Job Work:** Aristo provides specialized **packaging and job work services**, tailoring formulations and delivery systems to the specific requirements of domestic and international institutional clients.
* **Professional Financial Services:** Uniquely, the firm maintains a specialized division providing **Audit, Taxation, and Management Consultancy**. This branch handles complex corporate actions including **U.S./U.K. GAAP conversions**, **Project Finance (loan syndication)**, and **Statutory Audits** for nationalized banks and private entities.
---
### **Manufacturing Infrastructure & Quality Assurance**
The company’s operational backbone is centered in Gujarat, leveraging state-of-the-art technology to maintain rigorous global standards.
* **Production Hub:** Located at **G.I.D.C. Manjusar, Vadodara**, the facility spans three strategic plots (**E-24, 25, and 26**).
* **Advanced Laboratory Capabilities:** In-house quality control is managed via **High Performance Liquid Chromatography (HPLC)**, **Ultraviolet Spectrography (UV)**, and **Gas Chromatography (GC)** to ensure the integrity of raw materials and finished goods.
* **Regulatory Compliance:** All packaging (HDPE, Tin, Pet bottles) adheres strictly to **FAO** and **Bureau of Indian Standards (BIS)** guidelines.
* **Sustainable Operations:** The company has integrated **solar technologies** for facility lighting and is actively researching **eco-friendly, low-toxicity formulations** and **biological agrochemicals**.
---
### **Market Reach & Strategic Partnerships**
Aristo has established a robust footprint across both domestic and international agricultural markets.
* **Domestic Presence:** Supplies products across **20 Indian states**, with deep penetration in major hubs like **Punjab, Maharashtra, Gujarat, and Uttar Pradesh**.
* **Global Export Footprint:** Currently exports to **15 countries**, including **Germany, Italy, Australia, South Africa, UAE, and Vietnam**.
* **Institutional Empanelment:** A significant growth driver is the company’s empanelment with **National Fertilizers Limited (NFL)**. As an approved supplier of **Technical Grade Molecules**, Aristo supports NFL’s **Bathinda Unit**, securing a steady stream of high-volume institutional orders.
---
### **Financial Performance & Capital Structure**
Aristo has demonstrated consistent top-line and bottom-line growth, meeting key revenue and debt reduction guidance.
| Metric | FY 2023-24 | FY 2022-23 | Growth (%) |
| :--- | :--- | :--- | :--- |
| **Revenue from Operations** | **₹ 245.15 Crore** | **₹ 217.86 Crore** | **12.53%** |
| **Net Profit** | **₹ 3.90 Crore** | **₹ 3.56 Crore** | **9.36%** |
| **Export Sales** | **₹ 7.93 Crore** | - | - |
| **Import Purchases** | **₹ 6.30 Crore** | - | - |
**Capital & Shareholder Information:**
* **Authorized Share Capital:** **Rs. 8,00,00,000**
* **Paid-up Share Capital:** **Rs. 6,80,78,000** (comprising **68,07,800** equity shares).
* **Dividend Policy:** Declared a final dividend of **₹ 0.4 per share** (**4%**) for FY 2023-24.
* **Investment Capacity:** Shareholders approved an increase in investment and loan limits up to **Rs. 150.00 Crores** under **Section 186**, providing significant "dry powder" for strategic acquisitions or corporate lending.
---
### **Order Book Momentum (FY 2025-26)**
The company has secured a high-velocity order book from both global corporations and Indian PSUs:
| Client | Product/Category | Value (Approx.) |
| :--- | :--- | :--- |
| **National Fertilizers Ltd (NFL)** | Various Agrochemicals (Multiple LOIs) | **₹ 24.41 Crore (Cumulative)** |
| **Hindustan Agro** | Cypermethrin, Fipronil, Alphalite | **₹ 2.42 Crore** |
| **Sinochem India** | **Glyphosate Technical 95%** | **₹ 3.45 Crore** |
| **DVA Agro GmbH (Germany)** | **THODAN SUPER 35 SC** | **USD 230,805 (~₹1.98 Cr)** |
| **AVIMA (Pty) Ltd** | Chemicals (Overseas) | **USD 144,000 (~₹1.32 Cr)** |
| **Mizushi India Pvt Ltd** | Various Agrochemicals | **₹ 1.52 Crore** |
---
### **Strategic Growth Drivers & Product Innovation**
Aristo is positioning itself to capitalize on the projected **8-10% growth rate** of the Indian agrochemical sector through 2025.
* **Technical Grade Expansion:** Secured **Section 9(4) Registrations** for the import of **Acetamiprid Technical 99%** and **Atrazine Technical 98%**, allowing for higher-margin production.
* **Product Pipeline:** Holds **257 products** registered with the **CIB&RC**, providing a massive library of solutions for diverse pest profiles.
* **Digital Agriculture:** Participation in the **"Digital Agriculture Mission"** to modernize supply chains and leverage AI-driven platforms for precision farming.
* **Macro Tailwinds:** Rising global population (projected **970 crore by 2050**) and declining arable land per capita necessitate the intensive crop protection Aristo provides.
---
### **Risk Factors & Governance Framework**
Investors should monitor several operational and regulatory challenges inherent to the sector.
* **Climatic & Inventory Risk:** Erratic rainfall can lead to **weak demand** and **elevated inventory levels**, which recently caused **increased sales returns** and margin compression.
* **Global Competition:** Stiff competition from **low-cost Chinese imports** remains a persistent threat to domestic pricing power.
* **Regulatory Compliance:** The company operates under the **Insecticides Act (1968)** and **SEBI Regulations**. It has previously faced an **NSE SOP fine** (May 2024) for delays in appointing a Qualified Company Secretary and procedural lapses in maintaining the **Structured Digital Database (SDD)**.
* **Management Evolution:** The Board has revised the remuneration for **CMD Narendra Singh Barhat** to a ceiling of **₹ 75,00,000 per annum** (effective Sept 2025), reflecting the company's scaling operations and increased management responsibilities.